Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Executive Summary

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

You may also be interested in...



EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche

Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said

EPO Safety Review Will Be Closely Watched By Amgen, J&J And Roche

Roche will refine its development program for the continuous erythropoeisis receptor activator (CERA) R-744 based on an upcoming FDA advisory committee discussion of EPO safety issues, Worldwide Pharmaceuticals Head William Burns said

Enbrel Once-Weekly Dosing Will Help “Neutralize” Humira Advantage – Amgen

Amgen hopes a once-weekly dosing regimen for Enbrel will help offset Humira's biweekly dosing advantage, Exec VP-Global Communications Operations George Morrow says

Related Content

UsernamePublicRestriction

Register

PS042253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel